CARSGEN-B (02171.HK): In Vivo CAR-T CT1182 Yields 3 CRs in Six Patients

On 22 November 2026, CARSGEN-B (02171.HK) reported early data for in vivo CAR-T CT1182, with three complete and two partial responses among six evaluable patients.

NewTimeSpace News: On 22 November 2026, CARsgen Therapeutics Holdings Limited (stock code: 02171.HK) announced on a voluntary basis preliminary clinical data for CT1182 (KJ-C2529), a CD19/CD20-targeting in vivo CAR T-cell product candidate developed on its proprietary CARvivo® platform, for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. The Company said the candidate showed preliminary favourable safety and encouraging efficacy signals.

As of 31 October 2026, the dose-exploration range was 1.2×10⁸ TU to 7.2×10⁸ TU, with five patients with diffuse large B-cell lymphoma and one with blastoid mantle cell lymphoma enrolled. All six patients had aggressive lymphoma subtypes with Ann Arbor Stage IV disease, a median of three prior lines of therapy and a median total tumour burden (SPD) of 1,927.5 mm², and two had prior T-cell engager treatment. Median follow-up was about 3.2 months; among the six efficacy-evaluable patients, three achieved complete response and two partial response, with all responses ongoing as at the cut-off date. Complete response was observed at the starting dose, the longest response has lasted nearly five months, and complete response was also seen in one T-cell engager-refractory patient.

On safety, among the six DLT-evaluable patients, no treatment-related serious adverse events, dose-limiting toxicities or infusion-related reactions were observed, and there was no infusion-related biphasic cytokine elevation, immune effector cell-associated haemophagocytic lymphohistiocytosis-like syndrome or immune effector cell-associated neurotoxicity syndrome; only Grade 1 cytokine release syndrome occurred. Haematotoxicity was mild, with no treatment-related Grade 3 or above haematological toxicity other than one case of Grade 3 leukopenia that could not be fully ruled out as disease-related. The Company said the early data validate the safety and gene delivery of the CARvivo® platform and that the safety profile supports development of an outpatient setting; complete B-cell aplasia was observed in all responding patients, suggesting potential use in other B-cell diseases such as autoimmune diseases. It plans to explore a broader dose range in subsequent trials to identify the recommended Phase 2 dose and expects to file for a registrational clinical trial in the first half of 2027. The announcement carries the Rule 18A.05 warning that the Company cannot guarantee it will successfully develop or ultimately commercialise CT1182.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.